NCT06548919 - Current Status of Treatment for Chinese Patients With ESR1-mutated HR+/HER2-advanced Breast Cancer | Biotech Hunter

Enrollment

450

Participants

Timeline

Start Date

August 8, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2027

Conditions

ESR1 Gene MutationAdvanced Breast Cancer

Interventions

DRUG

Endocrine therapy

All endocrine treatment regimens approved for advanced breast cancer, including tamoxifen, aromatase inhibitors, fulvestrant, etc.

DRUG

Chemotherapy Prednisone

All chemotherapy treatment regimens approved for advanced breast cancer

Trial Locations (1)

RECRUITING

Tianjin Haidafu Internet Hospital, Suzhou